Industry News
Biotechnology Industry News
After failed SPAC and phase 3 fumble, Amicus gene therapy hits another delay to approval
After failed SPAC and phase 3 fumble, Amicus gene therapy hits another delay to approval jwaldron Wed, 05/11/2022 - 09:43
After phase 3 fumble and failed SPAC, Amicus’ Pompe disease drug hits another delay to approval
After phase 3 fumble and failed SPAC, Amicus' Pompe disease drug hits another delay to approval jwaldron Wed, 05/11/2022 - 09:43
Inovio CEO departs, leaving Jacqueline Shea in charge of ‘particularly challenging period’ in the DNA vaccine biotech’s history
Inovio CEO departs, leaving Jacqueline Shea in charge of 'particularly challenging period' in the DNA vaccine biotech's history aarmstrong Wed, 05/11/2022 - 09:30
Inflammation space swells further as Nuvig unveils $47M to transform autoimmune therapies
Inflammation space swells further as Nuvig unveils $47M to transform autoimmune therapies jwaldron Wed, 05/11/2022 - 07:47
Takeda scraps dream of getting rare disease drug to market in latest setback to Wave 1 pipeline
Takeda scraps dream of getting rare disease drug to market in latest setback to Wave 1 pipeline ntaylor Wed, 05/11/2022 - 07:29
Strike 2: Roche flunks another phase 3 lung cancer test to leave TIGIT space reeling
Strike 2: Roche flunks another phase 3 lung cancer test to leave TIGIT space reeling ntaylor Wed, 05/11/2022 - 03:33
Can FDA replicate Operation Warp Speed for rare diseases? Not yet, but Peter Marks has some ideas
Can FDA replicate Operation Warp Speed for rare diseases? Not yet, but Peter Marks has some ideas mbayer Tue, 05/10/2022 - 18:26
Rallybio wades into Sanofi storeroom for $3M rare disease deal
Rallybio wades into Sanofi storeroom for $3M rare disease deal aarmstrong Tue, 05/10/2022 - 12:33
Cortexyme shakes things up with Novosteo acquisition, leadership change and a new name
Cortexyme shakes things up with Novosteo acquisition, leadership change and a new name gmasson Tue, 05/10/2022 - 10:26
Starting gun? $11.6B M&A domino falls as Pfizer scoops up Biohaven for phase 3 migraine nasal spray
Starting gun? $11.6B M&A domino falls as Pfizer scoops up Biohaven for phase 3 migraine nasal spray mbayer Tue, 05/10/2022 - 09:25
Adimab swaps scientist for lawyer as CEO Tillman Gerngross steps down after 15 years
Adimab swaps scientist for lawyer as CEO Tillman Gerngross steps down after 15 years jwaldron Tue, 05/10/2022 - 08:38
Moneybags Nuvation deprioritizes 2 solid tumor prospects to narrow focus onto 3 candidates
Moneybags Nuvation deprioritizes 2 solid tumor prospects to narrow focus onto 3 candidates ntaylor Tue, 05/10/2022 - 08:23
Idorsia drug fails to quell binge eating in midphase trial, driving biotech to abandon the indication
Idorsia drug fails to quell binge eating in midphase trial, driving biotech to abandon the indication ntaylor Tue, 05/10/2022 - 06:26
Eisai wraps filing for Biogen-partnered Aduhelm followup, hoping to regain ‘credibility and trust’
Eisai wraps filing for Biogen-partnered Aduhelm followup, hoping to regain 'credibility and trust' aarmstrong Mon, 05/09/2022 - 15:54
Eisai wraps filing for Biogen-partnered Aduhelm follow-up, hoping to regain ‘credibility and trust’
Eisai wraps filing for Biogen-partnered Aduhelm follow-up, hoping to regain 'credibility and trust' aarmstrong Mon, 05/09/2022 - 15:54
More Moma: $150M series B will push precision cancer drugs to clinic by 2024
More Moma: $150M series B will push precision cancer drugs to clinic by 2024 gmasson Mon, 05/09/2022 - 15:13
Sesen Bio reports progress with regulators as it preps for new cancer trial, but issues remain
Sesen Bio reports progress with regulators as it preps for new cancer trial, but issues remain mbayer Mon, 05/09/2022 - 11:01
Investors take root in Aspen Neuroscience’s customized cell therapy as $147.5M round closes
Investors take root in Aspen Neuroscience’s customized cell therapy as $147.5M round closes gmasson Mon, 05/09/2022 - 10:45
LogicBio’s sun and shares rise again after FDA releases clinical hold on pediatric genome editing therapy
LogicBio's sun and shares rise again after FDA releases clinical hold on pediatric genome editing therapy aarmstrong Mon, 05/09/2022 - 10:11
J&J axes Bavarian Nordic pact for HPV and Hep B vax, keeps two other programs
J&J axes Bavarian Nordic pact for HPV and Hep B vax, keeps two other programs mbayer Mon, 05/09/2022 - 09:53